Cognizant, Capgemini slide into sub-revenue valuation territory

Bengaluru: A tale of two companies: both Cognizant and Capgemini are now trading at market capitalisations below their annual revenue. It is a striking signal of investor caution toward businesses operating on mid-teen margins, a characteristic of the IT services sector that offers little cushion when growth slows.Cognizant's market capitalisation stood at $22.3 billion as of Friday, down 22% over the past month and 44% over the past year. That places it near the lower end of the company’s FY26 revenue guidance of $22.1 billion to $22.6 billion. Its full-year outlook factors in recently completed acquisitions, with 3Cloud and Astreya expected to contribute roughly 150 basis points to revenue growth. Capgemini tells a similar story. The French IT services company closed Friday with a market capitalisation of around $18 billion against trailing 12-month revenue of $22.4 billion.AI-native challengers are no longer staying in their lane. They are moving into services delivery and exploring acquisitions in the sector, forcing incumbent IT firms to rewire their operating models on the move—while simultaneously navigating macroeconomic headwinds, softer client spending, and AI-led pricing pressure. Phil Fersht, CEO of HfS Research, said, “US investors are obsessed with AI and we're in an era where people-heavy businesses are not fashionable."He said investors are no longer rewarding firms simply for scale, cash generation or incremental margin improvement. Instead, they want evidence that service providers can reinvent themselves around AI-led, outcome-based models and eventually decouple revenue growth from linear headcount expansion.“To Cognizant’s credit, Ravi Kumar has stabilised a business that was drifting strategically and operationally a couple of years ago. But the market is still questioning whether Cognizant can generate sustained premium growth and materially improve its margin structure in an environment where traditional application maintenance and labour-arbitrage models are coming under intense pressure from GenAI and agentic automation,” Fersht added.Kotak Institutional Equities flagged a similar concern in a recent note. “Guidance execution now faces two additional risks — weakness in the healthcare vertical and macro deterioration. The midpoint assumes an improved environment in the second half of CY26 compared with the present, even though conditions have worsened over the past one to two months. This also assumes AI-led deflation has been sufficiently absorbed,” the note said.The brokerage noted that Cognizant's third-party sales accounted for 47% of organic growth. However, the healthcare vertical is facing visible stress, effectively leaving growth dependent on a single vertical.Kotak added that growth in the 2026 calendar year could become increasingly dependent on third-party sales, similar to trends seen in the first quarter of 2026, potentially diluting growth quality.The brokerage also said margin pressure could stem from a combination of large-deal transition costs, AI investments, a greater contribution from third-party sales, pricing pressure in the core business, and integration costs associated with potentially onsite-heavy acquisitions beginning in the second quarter of calendar year 2026. In fact, an industry observer described them as tier-1 firms with tier-2 margins.